A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis
Ming Chao, Hao Wu, Kai Jin, Bin Li, Jianjun Wu, Guangqiang Zhang, Gong Yang, Xun Hu, Ming Chao, Hao Wu, Kai Jin, Bin Li, Jianjun Wu, Guangqiang Zhang, Gong Yang, Xun Hu
Abstract
Background: Previous works suggested that neutralizing intratumoral lactic acidosis combined with glucose deprivation may deliver an effective approach to control tumor. We did a pilot clinical investigation, including a nonrandomized (57 patients with large HCC) and a randomized controlled (20 patients with large HCC) study.
Methods: The patients were treated with transarterial chemoembolization (TACE) with or without bicarbonate local infusion into tumor.
Results: In the nonrandomized controlled study, geometric mean of viable tumor residues (VTR) in TACE with bicarbonate was 6.4-fold lower than that in TACE without bicarbonate (7.1% [95% CI: 4.6%–10.9%] vs 45.6% [28.9%–72.0%]; p<0.0001). This difference was recapitulated by a subsequent randomized controlled study. TACE combined with bicarbonate yielded a 100% objective response rate (ORR), whereas the ORR treated with TACE alone was 44.4% (nonrandomized) and 63.6% (randomized). The survival data suggested that bicarbonate may bring survival benefit.
Conclusions: Bicarbonate markedly enhances the anticancer activity of TACE.
Funding: Funded by National Natural Science Foundation of China.
Clinical trial number: ChiCTR-IOR-14005319.
Keywords: bicarbonate; cancer biology; hepatocellular carcinoma; human; lactic acidosis; transarterial chemoembolization.
Conflict of interest statement
No competing interests declared.
Figures
References
- Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics. 2001;51:349–353. doi: 10.1016/S0360-3016(01)01630-3.
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology. 2001;35:421–430. doi: 10.1016/S0168-8278(01)00130-1.
- Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M, Chi JT. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLOS Genetics. 2008;4:e1000293. doi: 10.1371/journal.pgen.1000293.
- Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559–563. doi: 10.1038/nature13490.
- Dai C, Sun F, Zhu C, Hu X. Tumor environmental factors glucose deprivation and lactic acidosis induce mitotic chromosomal instability--an implication in aneuploid human tumors. PLOS One. 2013;8:e63054. doi: 10.1371/journal.pone.0063054.
- El-Serag HB. Hepatocellular carcinoma. New England Journal of Medicine. 2011;365:1118–1127. doi: 10.1056/NEJMra1001683.
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet. 2012;379:1245–1255. doi: 10.1016/S0140-6736(11)61347-0.
- Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature Reviews Cancer. 2004;4:891–899. doi: 10.1038/nrc1478.
- Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. Journal of Hepatology. 2011;55:1309–1316. doi: 10.1016/j.jhep.2011.03.007.
- Haas R, Smith J, Rocher-Ros V, Nadkarni S, Montero-Melendez T, D'Acquisto F, Bland EJ, Bombardieri M, Pitzalis C, Perretti M, Marelli-Berg FM, Mauro C. Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions. PLOS Biology. 2015;13:e1002202. doi: 10.1371/journal.pbio.1002202.
- Ibrahim-Hashim A, Cornnell HH, Abrahams D, Lloyd M, Bui M, Gillies RJ, Gatenby RA. Systemic buffers inhibit carcinogenesis in TRAMP mice. The Journal of Urology. 2012;188:624–631. doi: 10.1016/j.juro.2012.03.113.
- Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. European Journal of Surgical Oncology. 2005;31:331–347. doi: 10.1016/j.ejso.2004.10.011.
- Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Hepatology. 2013;58:1181–1187. doi: 10.1016/j.jhep.2013.01.039.
- Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the study of the liver criteria in hepatocellular carcinoma following chemoembolisation. European Journal of Cancer. 2013;49:826–834. doi: 10.1016/j.ejca.2012.08.022.
- Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, Park JY, Kim do Y, Ahn SH, Kim MD, Park SI, Won JY, Lee do Y, Han KH. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. Journal of Hepatology. 2015;62:1304–1310. doi: 10.1016/j.jhep.2015.01.022.
- Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. Journal of Clinical Oncology. 2015;33:1835–1844. doi: 10.1200/JCO.2014.60.1153.
- Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–442. doi: 10.1053/jhep.2003.50047.
- Martin NK, Gaffney EA, Gatenby RA, Gillies RJ, Robey IF, Maini PK. A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Mathematical Biosciences. 2011;230:1–11. doi: 10.1016/j.mbs.2010.12.002.
- Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. British Journal of Cancer. 2012;106:1280–1287. doi: 10.1038/bjc.2012.58.
- Partecke IL, Kaeding A, Sendler M, Albers N, Kühn JP, Speerforck S, Roese S, Seubert F, Diedrich S, Kuehn S, Weiss UF, Mayerle J, Lerch MM, Hadlich S, Hosten N, Heidecke CD, Puls R, von Bernstorff W. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. BMC Cancer. 2011;11:40. doi: 10.1186/1471-2407-11-40.
- Paschen W, Djuricic B, Mies G, Schmidt-Kastner R, Linn F. Lactate and pH in the brain: association and dissociation in different pathophysiological states. Journal of Neurochemistry. 1987;48:154–159. doi: 10.1111/j.1471-4159.1987.tb13140.x.
- Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R, Wang E, Baker T, Abecassis M, Benson AB, Nemcek AA, Omary R, Salem R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062–1069. doi: 10.1001/jama.2010.262.
- Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF, Baker T, Wang E, Gupta R, Nayar R, Benson AB, Abecassis M, Omary R, Salem R. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. Journal of Hepatology. 2011;54:695–704. doi: 10.1016/j.jhep.2010.10.004.
- Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Research. 2009;69:2260–2268. doi: 10.1158/0008-5472.CAN-07-5575.
- Schwickert G, Walenta S, Sundfør K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Research. 1995;55:4757–4759.
- Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–718. doi: 10.1148/radiol.11110282.
- Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. Journal of Hepatology. 2015;62:1187–1195. doi: 10.1016/j.jhep.2015.02.010.
- Silva AS, Yunes JA, Gillies RJ, Gatenby RA. The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. Cancer Research. 2009;69:2677–2684. doi: 10.1158/0008-5472.CAN-08-2394.
- Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation. 2008;118:3930–3942. doi: 10.1172/JCI36843.
- Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Research. 2011;71:2550–2560. doi: 10.1158/0008-5472.CAN-10-2828.
- Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. The American Journal of Pathology. 1997;150:409–415.
- Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research. 2000;60:916–921.
- Wu H, Ding Z, Hu D, Sun F, Dai C, Xie J, Hu X. Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. The Journal of Pathology. 2012;227:189–199. doi: 10.1002/path.3978.
- Xie J, Wu H, Dai C, Pan Q, Ding Z, Hu D, Ji B, Luo Y, Hu X. Beyond Warburg effect – dual metabolic nature of cancer cells. Scientific Reports. 2014;4:4927. doi: 10.1038/srep04927.
- Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. Journal of Magnetic Resonance Imaging. 2007;25:992–999. doi: 10.1002/jmri.20902.
Source: PubMed